3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
6
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Dermatologic
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
1307
Carcinoma, Renal Cell
660
Urinary Bladder Neoplasms
405
Carcinoma, Non-Small-Cell Lung
333
Neoplasms
301
Carcinoma, Transitional Cell
263
Breast Neoplasms
252
Ovarian Neoplasms
248
Melanoma
235
Colorectal Neoplasms
227
Neoplasm Metastasis
214
Kidney Neoplasms
200
Pancreatic Neoplasms
169
Stomach Neoplasms
162
Squamous Cell Carcinoma of Head and Neck
143
Lung Neoplasms
140
Uterine Cervical Neoplasms
123
Non-Muscle Invasive Bladder Neoplasms
118
Triple Negative Breast Neoplasms
112
Head and Neck Neoplasms
111
Endometrial Neoplasms
109
Esophageal Neoplasms
107
Carcinoma, Hepatocellular
97
Small Cell Lung Carcinoma
80
Sarcoma
75
Colonic Neoplasms
55
Urologic Neoplasms
53
Prostatic Neoplasms, Castration-Resistant
47
Liver Neoplasms
47
Cholangiocarcinoma
43
Interventions
pazopanib
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Patient Preference
×
Genitourinary
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts